pdf

Off-Label Marketing and Use of Drugs and Devices: Where Have We Been and Where are We Going?

January 1, 0001
O'Melveny Los Angeles partner David Deaton and counsel Houman Ehsan recently co-authored an article entitled "Enforcement Related to Off-Label Marketing and Use of Drugs and Devices: Where Have We Been and Where are We Going?" in the January 2009 issue of the American Health Lawyers Association's Journal of Health & Life Science Law.

The article analyzes the legal and medical standards associated with off-label use and marketing of drugs, provides summaries of recent enforcement activities regarding off-label marketing, and explains the current federal regulatory issues surrounding off-label marketing practices. The article also provides practical-pointers on regulatory compliance and the risks associated with fraud and abuse laws for drug companies and practitioners.